Fenofibrate

Fenofibrate capsules Fenogal fenofibrate ; 200mg capsules have been introduced Genus Pharmaceuticals pack size 30, 14.75. APS Berk introductions The following products have been introduced APS Berk ; : Co-codamol 500 8 tablets; pack size 32, 0.85 Ferrous sulphate 200mg tablets; 100, 3.21 Gliclazide 80mg tablets; 60, 6.96 Paracetamol 500mg caplets; 32, 0.85 Diltiazem XL capsules Diltiazem hydrochloride XL modified-release capsules have been launched PLIVA Pharma net price 180mg 28 7.55, Diethylstilbestrol extension The expiry date for batch 500940 of APS Berk's diethylstilbestrol stilboestrol ; 5mg tablets has been extended by 12 months to December 2003 following a batch-specific licence variation. This is the only stock of this product available. Cartons and blisters have been overlabelled with the new expiry date. Details from APS 01323 501111. Phosphate enema Fletcher's phosphate long tube enema has been reformulated in plastic bottles with a separate applicator, extension tube and nozzle for attachment before use Forest Laboratories ; . The long tube bag version is discontinued. Details from Forest on 01322 550550. Rosemont solutions Rosemont Pharmaceuticals has launched the following as licensed products: Cimetidine 200mg 5ml sugar free oral solution, peach and peppermint flavour; net price, 300ml 14.24 Dipyridamole 50mg 5ml oral suspension, almond and menthol flavour; net price 150ml 34 A number of senior professional managers within pharmacy organisations recently took part in a 210-mile sponsored cycle ride from London to Paris in aid of Great Ormond Street Childrens Charity. They expect to raise around 25, 000. The photograph shows the riders, who included John D'Arcy National Pharmaceutical Association ; , Ciaran McSorley Lloydspharmacy ; , Andy Wills SSL International ; , Tim Holmes SSL ; , Ken Watkinson Phoenix Healthcare Distribution ; , Tony Bradshaw Phoenix ; , David Watson Phoenix ; , Paul Smith Rowlands Pharmacy ; , Mike Blakeman Rowlands ; , Jo Skipper GlaxoSmithKline ; , Vicky Hampson GSK ; , Richard Goldberg GM-B ; , Dave Haydon Profile Shopfitters ; , Marshall Glynn G-Pharma ; and Rick Manners G-Pharma.
Abbreviations: SD, stable disease; PD, progressive disease; ND, no measurable disease; NA, not available because no surgery was done post-vaccination. * ``Positive'' CTL response was set as % specific lysis post-vaccine d 35 ; 2 magnitude of % specific lysis pre-vaccine d 14 ; at two or more E Tratios. cTGF-h2 expression is presented as quantitative units relative to primer controls and normalized to glyceraldehyde-3-phosphate dehydrogenase expression. bScored by semiquantitative assessment of number of CD8 + TILs and flavoxate, because lipidil fenofibrate. To evaluate the current utilization of LLDs in a Canadian province, the population-wide Pharmanet database was examined for the years 1996 and 1997. The database collects information on drug prescriptions filled by every individual through out the province. It contains information on the drug prescribed, the date on which the prescription was filled, the numbers of refills, the prescribing physician, a personal health number PHN ; , the age and gender of the patient, and the cost of the prescription. This system was implemented in mid-1995. Only data collected after January 1, 1996 was considered in this study. In order to determine the number of prescriptions filled for LLDs from January 1996 to December 1997, the number of personal health numbers PHNs ; with a drug identification number DIN ; corresponding to a LLD were extracted. The list of DINs used in this study is presented in Appendix A. The DINs were divided into statins and non-statins. The statins category included prescriptions for pravastatin, simvastatin, atorvastatin, fluvastatin and lovastatin. Cerivastatin was not on the market in BC in 1996 and 1997. The non-statin category included: the bile acid sequestrants cholestyramine, colestipol ; , the fibrates clofibrate, fenofibrate, gemfibrozil ; , as well as probucol and niacin. Each PHN was counted only once based on the first LLD prescription filled. Individuals prescribed both a statin and non-statin LLD were counted only once and categorized as receiving "both" types of LLDs. To distinguish between prescriptions made to individuals without established heart disease primary prevention ; or with established heart disease angina or myocardial infarction MI ; , secondary prevention ; , the date of the first LLD prescription was compared to the date of the first reporting of an ICD-9 code corresponding to angina or MI in the Medical Services Plan MSP ; database. The MSP database uses the same PHN as the Pharmanet database allowing us to link available data. The list of ICD-9 codes used is presented in Appendix B. The MSP database was examined for the relevant ICD-9 codes from 1990 onwards. The data extracted was stratified by five-year age group and gender female, male or unknown ; . Age groups were assigned based on the age on the day of the first LLD. 3. Tablet properties Weight .165 mg Diameter .8 mm Form .biplanar Hardness.44 N Disintegration . 1 min Friability . 0.1 and urispas.

In calculating a new basal dose, where controversy exists as to the correct conversion value, it is safest initially to use a conversion value that will result in a more conservative low ; new drug dose relative to the old dose.
Table 2. Saturation Solubility and Relative Sink Conditions of Fenofibrafe at Different Surfactant Concentrations * Medium DI water 0.025 M ~0.72% ; SLS 0.05 M ~1.44% ; SLS 0.075 M ~2.16% ; SLS 0.1 M ~2.88% ; SLS 2% ~0.015 M ; Tween 80 Saturation solubility g mL ; 0.8 195.3 445.9 CS CD 54 mg tablet ; 0.015 3.6 8.26 CS CD 160 mg tablet ; 0.005 1.22 2.79 and flunarizine. All these Magistrates look after the works of about 125 Police Stations which maintain the law and order in Delhi having population of about 1.20 crores. There are 8 Mahila Courts dealing exclusively with the Magistrate triable cases related to women. Some designated Courts are dealing with cases relating to Negotiable Instruments Act. Apart from the aforesaid work, the office of the CMM is also controlling the Special MMs Traffic ; which are 22 in numbers having their Courts at 8 places in Delhi viz. Kirpa Narain Marg, Under Hill Road, Burari, Raja Garden, Parliament Street, Kapashera, Saket and Karkardooma. These Magistrates are regulating the traffic cases of the entire Delhi by disposing off the challans issued by the Traffic Police against the traffic offenders. CMM office has also to see the affairs of the 8 Spl. MMs Municipal Magistrates 7MCD + 1 NDMC ; who sits in zones of Delhi and 23 Special Municipal Magistrates who are looking after the work related to Littering, Sanitation and Public Health of wards assigned to them for keeping entire Delhi clean and hygienic. The aforesaid 23 Special Magistrates have been appointed by the Hon'ble Delhi High Court only one year ago and they are handling efficiently their respective tasks in their own wards areas. In the office of the CMM following staff is working: Sl. No. 1. 2. 3. Type of Staff Superintendent Incharge Assistant UDC LDC Peons Numbers 01 TOTAL 21. Dopamine receptor medical concerns by any trial tha insurance and flupenthixol. ANTIRETROVIRALS NRTIs- abacavir Ziagen ; , abacavir lamivudine Epzicom ; , abacavir lamivudine zidovudine Trizivir ; , didanosine ddI, Videx, Videx EC ; , efavirenz emtricitabine tenofovir disproxil fumarate Atripla ; , emtricitabine Emtriva ; , lamivudine Epivir, 3TC ; , lamivudine zidovudine Combivir ; , stavudine d4T, Zerit ; , tenofovir emtricitabine Truvada ; , zalcitabine ddC, Hivid ; , zidovudine AZT, Retrovir ; . PIs- amprenavir Agenerase ; , atazanavir Reyataz ; , darunavir Prezista ; , fosamprenavir Lexiva ; , indinavir Crixivan ; , lopinavir ritonavir Kaletra ; , nelfinavir Viracept ; , ritonavir Norvir ; , saquinavir Fortovase, Invirase ; . NNRTIs- delavirdine Rescriptor ; , efavirenz Sustiva ; , nevirapine Viramune ; , tipranavir Aptivus ; . Entry Inhibitors- enfuvirtide Fuzeon ; . OI DRUGS PHS "A1 OI"s- acyclovir Zovirax ; , amphotericin B Fungizone ; , azithromycin Zithromax ; , cidofovir Vistide ; , clarithromycin Biaxin ; , clindamycin phosphate Cleocin Phosphate ; , famciclovir Famvir ; , fluconazole Diflucan ; , isoniazid INH ; , itraconazole Sporonox ; , leucovorin Folinic Acid ; , pentamidine Nebupent, Pentam ; , pyrazinamide, pyrimethamine Daraprim ; , rifabutin Mycobutin ; , rifampin Rifadin, Rifater, Rimactane ; , sulfadiazine, TMP SMX Bactrim, C0-Trimoxazole, Septra, Sulfatrim ; , valacyclovir hydrochloride Valtrex ; , valganciclovir Valcyte ; . Other OIs- amoxicillin Amoxil, Trimox, Wymox ; , atovaquone Mepron ; , cephalexin monohydrate Keflex ; , ciprofloxacin Cipro ; , clindamycin HCL Cleocin HCL ; , clindamycin palmitate Cleocin pediatirc ; , clotrimazole Mycelex, Lotrimin ; , dapsone DDS ; , dicloxacillin sodium Dycill, Dynapen, Pathocil ; , ethambutol Myambutol ; , ketoconazole Nizoral ; , miconazole Monistat ; , nystatin Mycostatin ; , ofloxacin Floxin ; , paromomycin sulfate Humatin ; , primaquine phosphate, streptomycin sulfate, sulfamethoxazole Gantanol, Urobak ; , terconazole Terazol 3, 7 ; , trimethoprim TMP, Proloprim, Trimpex ; . ALL OTHERS atorvastatin Lipitor ; , ezetimibe Zetia ; , fenofibrate Tricor ; , pravastatin Pravachol ; , dronabinol Marinol ; , megestrol acetate Megace ; , Lomotil, Imodium, atorvastatin Lipitor ; , cefixime Suprax ; , chlorhexidine gluconate Peridex, PerioGard ; , danazol Danocrine ; , doxycycline Doryx, Vibramycin, Vibra-Tabs ; , erythromycin ethylsuccinate E.E.S. ; , ezetimibe Zetia ; , fenofibrate Tricor ; , interferon alpha-2b Intron A ; , multivitaminsminerals, penicillin VK, pravastatin Pravachol ; , tetracycline Achromycin V, Sumycin, Tetracyn. Testimony of the witnesses, review of the medical reports and other documentary evidence, application of the appropriate statutory provisions and case law, I make the following: FINDINGS 1. 2. The Arkansas Workers' Compensation Commission has jurisdiction of this claim. On April 19, 2004, the relationship of employee-employer-carrier existed among and fluvoxamine.
Scanner 200, Pie Medical, Maastricht, The Netherlands ; , which consists of an ultrasound imager with a 10 MHz linear array transducer connected to a data acquisition system and a personal computer. Three measurements were averaged to calculate a baseline diameter. By inflation of a blood pressure cuff for 5-minutes at a pressure of 200 mmHg, ischaemia was applied to the forearm distal to the location of the transducer. Ultrasonography continued for 5-minutes after cuff release, with measurements at 30-second intervals. The widest lumen diameter was taken as a measure for maximal vasodilation. Nitroglycerin 400 g ; was used to determine endothelium-independent vasodilation. All measurements were performed by the same technician with patients supine in a quiet, temperature-controlled 21C ; environment after at least 15-minutes of rest. The operator was unaware of the assignment status of the patients. Endothelial function was measured before and 2-h after glucose ingestion. Analytical methods Total and high-density lipoprotein cholesterol, triglycerides, glucose, apolipoprotein B, creatinine, and serum asparate and alanine aminotransferases AST and ALT, respectively ; were measured using standard laboratory procedures, as described previously in detail31. LDL was isolated by ultracentrifugation31. Free fatty acids FFA ; were measured by an enzymatic colorimetric method Wako Chemicals GmbH, Neuss, Germany ; 31. For FFA measurement, a lipase inhibitor was added to the plasma in order to block ex vivo lipolysis. Insulin was measured by ELISA Mercodia, Uppsala, Sweden ; . Creactive protein CRP ; was measured using a high-sensitivity method Quantex hs-CRP kit, Biokit, S.A., Barcelona, Spain ; 32. Adiponectin was measured by ELISA R&D systems, Minneapolis, Minnesota, USA ; . CD4 cell counts were determined by flow cytometry, and HIV viral load was determined by ultrasensitive assay Statistical analysis Assumptions of normality were tested by Kolmogorov-Smirnov tests and by review of plots. Data are presented as means and standard deviations for variables with symmetric distribution, and as medians and interquartile ranges for variables with skewed distributions. Exact ninety-five percent confidence intervals for median differences were obtained by considering the full distribution of between treatment differences33. During the oral glucose tolerance test, total integrated area's under the curves AUC ; were calculated by the trapezoidal rule using GraphPad Prism version 4.0 GraphPad Software, San Diego, USA ; . Primary outcome measures were insulin AUC and subcutaneous and visceral abdominal fat. The secondary outcome measure was flow-mediated vasodilation. The primary analysis was to compare treatment effects between groups. For variables with symmetric distribution, we used t-tests on changes from baseline. For variables with skewed distributions, between treatment changes from baseline were compared with Mann-Withney tests. The secondary analysis was, for instance, field study fenofibrate.
Goodwill The Company accounts for goodwill in accordance with SFAS No. 142, "Goodwill and Other Intangible Assets." SFAS No. 142, among other things, requires that goodwill not be amortized but should be tested for impairment at least annually. The Company adopted this statement during the first quarter of fiscal 2003 by discontinuing the amortization of goodwill totaling $1.8 million per quarter $1.6 million net of tax ; . In addition, the Company reviews goodwill for possible impairment by comparing the fair value of each reporting unit to its carrying amount annually. Based on the Companys reviews, no impairment charges have been recorded. The following tables show the reported net income and earnings per share for fiscal year ended May 31, 2002, reconciles it to the adjusted net income and earnings per share had the nonamortization provisions of Statement 142 been applied beginning June 1, 2001, and compares it to the fiscal years ended May 31, 2004 and 2003 and luvox.

Learn more about irritable bowel syndrome the drug increases movement, so it helps those with irritable bowel syndrome characterized by constipation, said dr. The mma also establishes a prescription drug benefit beginning in 2006 for all medicare beneficiaries and folic. Chronic pain as a disease entity has not been fully appreciated, and there is a high prevalence of untreated or undertreated pain. Furthermore, there are farreaching consequences of chronic pain, which may include psychological morbidity, socioeconomic effects, social difficulties, and decreased quality of life.1, 2 The emphasis for managing a patient with chronic pain, therefore, is improving the clinical outcomes of functionality and quality of life. Although reducing the level of chronic pain is an important aspect of treatment, ameliorating or curing pain should not be expected, and development of a comprehensive treatment plan is most appropriate. In general, the PCP is trained and experienced in using a broad-based, biopsychosocial approach to patient care in medical practice. Yet, in the context of. The data clearly show that statins are effective in lowering the risk of heart attack as well as stroke as a part of both primary and secondary prevention programs. Nonetheless, in January of 2002, when the FDA attributed about 100 deaths to cerivastatin-induced rhabdomyolysis, many physicians became concerned about the safety of statins. Fearing possible rhabdomyolysis, members of the public often have stopped their statins with the occurrence of muscle aches and pains. Because of public awareness, statin package inserts, and concerns about liability, physicians routinely monitor transaminase and CPK levels in an effort to prevent serious statin-induced liver and or muscle toxicity. But some physicians question the necessity of closely monitoring transaminase levels. Their anecdotal experience suggests that these enzyme elevations are common, typically resolve despite continuing the statin dose unchanged ; and are generally believed to be due to a benign, non-statin related cause. While some physicians monitor CPK levels, package inserts recommend checking these tests only when patients develop muscle symptoms. While there is general consensus that those with significant liver disease, heavy alcohol consumption or chronic hepatitis should be prescribed statins only with extreme caution, data from a number of studies suggest that routine laboratory monitoring of transaminase and CPK levels may be of limited value. The CARE, LIPID, and WOSCOPS Prevastatin trials 112, 000 person years of exposure to Pravastatin ; showed the same number 1.4% ; of patients on Prevastatin as placebo with abnormal tramsaminase values. Additionally, there are no data demonstrating that liver enzyme measurements can predict severe liver injury. Large trials of Lovastatin AFCAPS TexCAPS ; as well as Simvastatin 4S, HPS ; did not show significant differences between the treatment and placebo arms for the incidence of abnormal liver function studies. The above mentioned trials did not reveal significant differences between treatment groups and placebo for elevated CPK or myopathy with or without rhabdomyolysis. While the combination of a statin and a fibrate Gemfibrozil or Fenfoibrate ; may increase the risk of myopathy, a recent study found that the incidence of myopathy with this combination was 0.12%. The new FDA-approved Simvastatin package insert recommends checking transaminase levels before starting therapy and then when clinically indicated. Recommendations for the 80mg dose are stricter. The package inserts for the other statins recommend stopping or decreasing the dose of the statin if LFT levels rise above 3X normal. The inserts do not specify the frequency of routine LFT testing. All statin package inserts recommend checking CPK levels only in the setting of weakness, myalgia, and muscle tenderness. Excluding cerevastatin, no statin has proven safer than others and fosinopril and fenofibrate.

In the Fehofibrate Intervention and Event Lowering in Diabetes FIELD ; study.36 A total of 9795 patients with type 2 DM were randomized to receive micronized fenofib4ate 200 mg d or placebo. At the 5-year follow-up, risk for the primary end point of first nonfatal myocardial infarction MI ; or CHD death was not significantly different between treatment groups HR, 0.89 [95% CI, 0.751.05] for fenofibrate; P 0.16 ; , but the risk for nonfatal MI and total CVD events was significantly reduced in the fenofivrate group 24% and 11%, respectively ; .36 However, interpretation of data from the FIELD study is difficult because of the much higher drop-in rate for statin therapy in the placebo group. Additional information is expected from the ongoing Action to Control Cardiovascular Risk in Diabetes ACCORD ; trial, 37 in which 10, 000 patients with type 2 DM are expected to be randomized in a double 2 factorial design. All patients will be randomized to intensive or standard glycemic control measured by glycosylated hemoglobin A1C ; 6.0% versus 7.0% to 7.9%. In the lipid component, 5800 patients will be randomized to receive fibrate plus statin combination therapy or statin monotherapy, and in the blood pressure component, 4200 patients will be randomized to intensive or standard control of systolic blood pressure 120 mm Hg vs 140 mm Hg ; . The primary end point is first major CVD event. Niacin Niacin increases HDL-C levels by 15% to 35%, decreases triglyceride levels by 20% to 50%, and decreases LDL-C levels by 5% to 25%.7 While concerns about glycemic control have limited the use of niacin in patients with insulin resistance, niacin at recommended doses of 2 g are not associated with worsening hyperglycemia.38 In the Coronary Drug Project CDP ; , 39 in which ~41% of patients randomized to niacin had elevat and geodon.
Table 2: Ahmad, N. et al.4 Meta-analysis Evidence Table.

Inhibition of HIV-1 infection by dehydroepiandrosterone in vitro Yang JY, Schwartz A, Henderson EE Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia 19140. Biochem Biophys Res Commun 1994 Jun 30; 201 3 ; : 1424-32 Human immunodeficiency virus type 1 HIV-1 ; isolated from patients with acquired immunodeficiency syndrome AIDS ; shows resistance to 3'azido-3' deoxythymidine AZT ; after one or two years of treatment. AZT also has significant toxic side effects, further limiting its use in the therapy of HIV-1infected individuals. Dehydroepiandrosterone DHEA ; has been shown to have a broad spectrum of biological functions, to be bioavailable orally and to be relatively nontoxic. Epidemiological studies provide evidence that reduced serum levels of DHEA are related to the progression of AIDS in HIV-1 infection. DHEA has also been shown to inhibit HIV-1 replication in vitro and block HIV-1 reactivation from chronically infected cell lines. However, there have been no reports on the ability of DHEA to inhibit the replication of AZT-resistant strains of HIV-1. We investigated whether DHEA treatment could inhibit replication of AZT-resistant strains of HIV-1. Addition of DHEA to MT-2 cell cultures infected with either AZT-sensitive or AZT-resistant isolates of HIV-1 resulted in dosedependent inhibition of HIV-1-induced cytopathic effect and suppression of HIV1 replication as measured by accumulation of reverse transcriptase activity. At a concentration as low as 50 microM, DHEA reduced AZT-resistant HIV-1 630.
Angioneurotic edema, angiotensin receptor antagonist, antidiabetic agent, atenolol, atorvastatin, beta adrenergic receptor blocking agent, bloating, body weight disorder, bronchospasm, calcium channel blocking agent, captopril, carvedilol, coughing, depression, dipeptidyl carboxypeptidase inhibitor, drug hypersensitivity, dyspepsia, erectile dysfunction, fatigue, fenofibrate, fibric acid derivative, gallstone, gastrointestinal symptom, gemfibrozil, heart muscle conduction disturbance, hepatitis, hydrochlorothiazide, hydroxymethylglutaryl coenzyme A reductase inhibitor, hypercholesterolemia, hyperkalemia, hypoglycemia, hypokalemia, hyponatremia, hypotension, impotence, inappropriate vasopressin secretion, insulin, kidney failure, lactic acidosis, lisinopril, losartan, meglitinide, metformin, metoprolol, myopathy, myositis, pravastatin, simvastatin, sulfonylurea derivative, tachycardia, thiazide diuretic agent, 2, 4 thiazolidinedione derivative, 1179 isotretinoin, abnormal substrate concentration in blood, hyperlipidemia, muscle atrophy, muscle stiffness, muscle weakness, myalgia, xerosis, 916 itraconazole, amphotericin B, aspergillosis, cost effectiveness analysis, voriconazole, liver toxicity, nephrotoxicity, 987 juvenile rheumatoid arthritis, corticosteroid, recombinant interleukin 1 receptor blocking agent, thalidomide, 1123 - Cushing syndrome, triamcinolone acetonide, adrenal cortex insufficiency, body weight disorder, 1138 kava extract, benzodiazepine derivative, bleeding, codeine, consciousness disorder, drug dependence, fluoxetine, fluvoxamine, imipramine, injury, kawain, liver failure, liver toxicity, memory disorder, paroxetine, sertraline, toxic hepatitis, valproic acid, 691 - drug approval, liver toxicity, 669 kidney carcinoma, bone metastasis, prostate cancer, zoledronic acid, arthralgia, bisphosphonic acid derivative, fatigue, fever, hematuria, hyperuricemia, kidney failure, micturition disorder, nausea, oliguria, vomiting, 700 kidney dysfunction, aging, drug overdose, enoxaparin, retroperitoneal hematoma, 1070 - basiliximab, liver failure, liver transplantation, bacteremia, cytomegalovirus infection, kidney failure, methylprednisolone, mycophenolic acid 2 morpholinoethyl ester, mycosis, Pneumocystis pneumonia, prednisone, tsukubaenolide, 1292 kidney failure, angiotensin receptor antagonist, benazepril, late onset kidney failure from angiotensin blockade, lisinopril, losartan, 940 kidney function, Crohn disease, mesalazine, interstitial nephritis, kidney failure, 1095 kidney graft rejection, acute graft rejection, cyclosporin A, drug monitoring, graft failure, kidney transplantation, gingiva hyperplasia, hirsutism, 1310 kidney transplantation, acute graft rejection, cyclosporin A, drug monitoring, graft failure, kidney graft rejection, gingiva hyperplasia, hirsutism, 1310 - 2 amino 2 [2 4 octylphenyl ; ethyl] 1, 3 propanediol, immunomodulating agent, bradycardia, heart atrium fibrillation, lymphocytopenia, 1294 - cancer risk, immunosuppressive agent, immunosuppressive treatment, breast cancer, colorectal cancer, cyclosporin, everolimus, kidney cancer, lung cancer, prostate cancer, rapamycin, skin cancer, solid tumor, target of rapamycin inhibitor, tsukubaenolide, 1309 - cyclosporin A, rapamycin, renal graft dysfunction, tsukubaenolide, anemia, face edema, hepatitis B, hypercholesterolemia, hypertension, intracranial hypertension, nephrotoxicity, opportunistic infection, proteinuria, skin cancer, thrombocytopenia, 1306 - cytomegalovirus infection, gastrointestinal infection, stomach ulcer, mycophenolic acid 2 morpholinoethyl ester, 680 Section 38 vol 41.2.

Follows that fibrates may exert a beneficial effect in this common disorder [58, 205-212]. CONCLUSIONS In conclusion, along with its well established lipid modifying effects, fenofibrate also exhibits several metabolic and pleiotropic properties [213] Fig. 1 ; . As consequence, fenofibrate monotherapy may represent the treatment of choice in patients with primary combined dyslipidaemia as well as in patients with specific forms of secondary dyslipidaemias such as diabetic dyslipidaemia and dyslipidaemias associated with the MetS and HIV infection. In addition, fenofibrate may diminish the hyperuricaemia of concurrently used medications e.g. diuretics ; . The combination of fenofibrate with statins is a treatment option in cases with refractory dyslipidaemia [44]. REFERENCES.